Evidence map›Paper›PMID 37656293›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2023

A study indicates an essential link between a mild deterioration in excretory kidney function and the risk of neutropenia during cancer chemotherapy.

Adriana Stryczyńska-Mirocha, Stanisław Łącki-Zynzeling, Maciej Borówka, Zofia I Niemir, Sylwia Kozak, Aleksander J Owczarek, Jerzy Chudek

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Adriana Stryczyńska-MirochaOncology Department - Section D, Katowice Oncology Center, Raciborska 27, 40-074, Katowice, Poland.
Stanisław Łącki-ZynzelingDepartment of Internal Medicine and Oncological Chemotherapy, Medical University of Silesia, Reymonta 8, 40-029, Katowice, Poland. s.lacki@outlook.com.
Maciej BorówkaDepartment of Internal Medicine and Oncological Chemotherapy, Medical University of Silesia, Reymonta 8, 40-029, Katowice, Poland.
Zofia I NiemirDepartment of Nephrology, Transplantology and Internal Diseases, Poznań University of Medical Sciences, Poznań, Al. Przybyszewskiego 49, 60-355, Katowice, Poland.
Sylwia KozakDepartment of Internal Medicine and Oncological Chemotherapy, Medical University of Silesia, Reymonta 8, 40-029, Katowice, Poland.
Aleksander J OwczarekHealth Promotion and Obesity Management Unit, Department of Pathophysiology, Medical University of Silesia, Medyków 18, 40-752, Katowice, Poland.
Jerzy ChudekDepartment of Internal Medicine and Oncological Chemotherapy, Medical University of Silesia, Reymonta 8, 40-029, Katowice, Poland.
Medical University of Silesia · PLPoznan University of Medical Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNeutropenia, defined as a number of neutrophils in patients' blood specimen lower than 1500 cells/μm

methodsThe study enrolled 38 patients starting chemotherapy, including 26 (68.4%) patients aged 65 years or more. The median duration of follow-up was 76 days. The methodology of creatinine assessment enabled the use of the recommended CKD-EPI formula for identifying patients with a mild reduction of glomerular filtration.

resultsSixteen (42.1%) patients developed at least G2 neutropenia without episodes of FN. Only five (13.1%) patients had eGFR < 60 ml/min/1.73 m

conclusionsOur observation indicates that even a mild reduction in eGFR is a risk factor for the development of neutropenia and a potential risk factor for FN. Authors are advised to check the author instructions for the journal they are submitting to for word limits and if structural elements like subheadings, citations, or equations are permitted.

Indexed as

NeoplasmsNeutropeniaRenal Insufficiency, ChronicHumansKidneyProspective StudiesChemotherapyCKD-EPIeGFRKidney function impairmentNeutropeniaNeutropenic fever

Identifiers

PMID37656293
PMCPMC10473980
OpenAlexW4386346700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.